Amgen secures $70m in biosimilar clash with Hospira
26-09-2017
ericsphotography / iStockphoto.com
A US district court has invalidated two patents owned by American pharmaceutical firm Hospira, in a victory for German healthcare company Fresenius Kabi.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Pfizer, Hospira, Fresenius Kabi, dexmedetomidine, patent invalidation, patent litigation, sedative, patent infringement
